X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CE-VST01-JC, is in clinical development as an allogeneic, off-the-shelf, JC-specific T-cell therapy (JC-VST) targeting JC polyoma virus (JCV) in patients that develop progressive multifocal leukoencephalopathy.
Lead Product(s): CE-VST01-JC
Therapeutic Area: Infections and Infectious Diseases Product Name: CE-VST01-JC
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
CE-VST01-JC, is in clinical development as an allogeneic, off-the-shelf, JC-specific T-cell therapy (JC-VST) targeting JC polyoma virus (JCV) in patients that develop progressive multifocal leukoencephalopathy.
Lead Product(s): CE-VST01-JC
Therapeutic Area: Infections and Infectious Diseases Product Name: CE-VST01-JC
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
Cellevolve will partner with innovators to bring a diverse and expansive portfolio of clinical stage cell therapy programs through late-stage development and deliver them as commercially available treatments.
Lead Product(s): Cell Therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Acclaimed Investors
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 18, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
